Noscira presents results of Nypta Gradually eliminate IIa clinical contest for the treatment of AD at ICAD 2010
– Treatment with Nypta(R) (Tideglusib) (NP-12) was tolerated and produced sure effects on Alzheimer’s patients in four of the five efficacy variables examined in the venture.
– In outlook of the favourable results of this bur, Noscira is preparing the next Gradually eliminate IIb annoyance on Alzheimer’s patients in lawfulness to furtherance with the clinical maturing of this blockbuster complicated.
Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs as rangoon runs neurodegenerative diseases, presented the results of a Stage IIa clinical enquiry of Nypta(R) (Tideglusib) on Alzheimer’s contagion (AD) at the Global Convention on Alzheimer’s Plague (ICAD), held in Honolulu (Hawaii) from July 10-15, 2010.
Help-Medical.net finds at this phrases:
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
